Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372893 | 0.85 | L3MBTL1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17330386 | 0.81 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2MAPTPDE4BLMNA | |
| SCHEMBL21419430 | 0.81 | AOC3 (0.41) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL17330385 | 0.81 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL3187563 | 0.80 | L3MBTL1 (0.48) | L3MBTL1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17330429 | 0.80 | SQOR (0.51) | L3MBTL1SMN1; SMN2PDE4BLMNAHTT | |
| SCHEMBL17343456 | 0.79 | GAA (0.39) | L3MBTL1MAPTMEN1KMT2ALMNA | |
| SCHEMBL15814853 | 0.78 | TSHR (0.46) | L3MBTL1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17372897 | 0.78 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL21419432 | 0.78 | ATP4A (0.42) | L3MBTL1SMN1; SMN2MEN1KMT2APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570121-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570121-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3521285-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521285-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190040047-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190040047-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3157915-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2015193768-A1 | ARYL FUSED LACTAMS AS EZH2 MODULATORS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193765-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.